+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals



Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals



Vaccine 22(25/26): 3329-3333



Presently, commercially available cell culture rabies vaccines for humans and animals consist of the five inactivated rabies virus proteins. The vaccines elicit a CD4+ helper T-cell response and a humoral B-cell response against the viral glycoprotein (G) resulting in the production of virus neutralizing antibody. Antibody against the viral nucleoprotein (N) is also present, but the mechanism(s) of its protection is unclear. HIV-infected individuals with low CD4+ T-lymphocyte counts and individuals undergoing treatment with immunosuppressive drugs have an impaired neutralizing antibody response after pre- and post-exposure immunization with rabies cell culture vaccines. Here we show the efficacy of live vaccinia-rabies virus recombinants, but not a cell culture vaccine consisting of inactivated rabies virus, to elicit elevated levels of neutralizing antibody in B-lymphocyte deficient A/WySnJ mice. The cell culture vaccine also failed to protect the mice, whereas a single immunization of a vaccinia recombinant expressing the rabies virus G or co-expressing G and N equally protected the mice up to 18 months after vaccination. The data suggest that recombinant poxviruses expressing the rabies virus G, in particular replication defective poxviruses such as canarypox or MVA vaccinia virus that undergo abortive replication in non-avian cells, or the attenuated vaccinia virus NYVAC, should be evaluated as rabies vaccines in immunocompromised individuals.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 004223201

Download citation: RISBibTeXText

PMID: 15308356

DOI: 10.1016/j.vaccine.2004.02.039


Related references

Development of an oral wildlife rabies vaccine immunization of raccoons by a vaccinia rabies glycoprotein recombinant virus and preliminary field baiting trials. Chanock, R M , Et Al (Ed ) Vaccines, 87 Modern Approaches to New Vaccines: Prevention Of Aids And Other Viral, Bacterial, And Parasitic Diseases; Conference, Cold Spring Harbor, New York, Usa, 1986 Xxiii+461p Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, Usa Illus Paper 389-392, 1987

Rabies virus glycoprotein expressed in a vaccinia virus recombinant vaccine cross protects mice against unique genetic variants of rabies viruses isolated worldwide. Journal of Cellular Biochemistry Suppl. 0(19A): 312, 1995

Combined immunization of DNA vaccine and replication-defective recombinant adenovirus bearing rabies glycoprotein gene induces immune response against rabies virus. Zhonghua Weishengwuxue He Mianyixue Zazhi 22(4): 403-406, 2002

Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection. Journal of Virology 65(6): 3400-3405, 1991

Immunization of foxes against rabies with a vaccinia recombinant virus expressing the rabies glycoprotein. Archives of Virology 102(3-4): 297-301, 1988

Immunization against rabies using a vaccinia-rabies recombinant virus expressing the surface glycoprotein. Vaccines 85: molecular and chemical basis of resistance to parasitic bacterial and viral diseases edited by Richard A Lerner Robert M Chanock Fred Brown: 162, 1985

Immunization against rabies using a recombinant vaccinia virus expressing the rabies glycoprotein. Genetical Research 45(2): 213, 1985

Human diploid cell culture rabies vaccine (HDCV) and purified chick embryo cell culture rabies vaccine (PCECV) both confer protective immunity against infection with the silver-haired bat rabies virus strain (SHBRV). Vaccine 16(17): 1656-1659, 1998

New generation of rabies vaccine. Vaccinia-rabies glycoprotein recombinant virus. Applied Virology Research, Volume 1 New Vaccines and Chemotherapy: 69-90, 1988

Oral vaccination of sheep against rabies with sad b19 vaccine or a vaccinia rabies recombinant virus 187xp. Annales de Medecine Veterinaire 131(6): 481-486, 1987

Rabies cell culture vaccines reconstituted and stored at 4 degrees C for 1 year prior to use protect mice against rabies virus. Vaccine 22(25-26): 3237-3239, 2004

Rabies cell culture vaccines reconstituted and stored at 4circleC for 1 year prior to use protect mice against rabies virus. Vaccine 22(25-26): 3237-3239, 2004

Protection of mice from rabies by intranasal immunization with inactivated rabies virus. Experimental Animals 57(1): 1-9, 2008

The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. Journal of Virology 71(5): 3677-3683, 1997

A single immunization with recombinant rabies virus (ERAG3G) confers complete protection against rabies in mice. Clinical and Experimental Vaccine Research 3(2): 176-184, 2014